CURRICULUM VITAE

Emma Cacciola

Aggregate Professor of Hematology

Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia”

 University of Catania

**Education/Training**

1982 M.D. Degree, Medical School, University of Catania

1985 Postgraduate Degree in Hematology, Institute of Hematology, University of Catania

1992 Postgraduate Degree in Oncology, Institute of General Pathology,University of Catania

**Research and Professional Experience:**

1982-1983 Medical Resident, Institute of Internal Medicine, University of Catania

1982-1984 Research Fellow, Postgraduate School in Hematology, University of Catania

* 1. Medical Resident, Institute of Physiopathology of Haemostasis, University of Catania
	2. Specialist Resident, Institute of Infective Diseases, University of Catania

1987-1996 Research Assistant, Institute of Hematology, University of Catania

1996 Assistant Professor of Hematology, Hematology Unit, University of Catania

1998-act Professor of Hematoolgy, Masterly Degree Course in Medicine, School of Medicine, University of Catania

1998-act Professor of Hematology, Specialization School of Hematology, School of Medicine, University of Catania

2001-act Professor of Hematology, I Level Degree Course in Biomedical Laboratory Techniques, School of Medicine, University of Catania

2004-2011 Professor of Hematology, Specialistic Degree Course in Health Biology, School of Mathematical, Physical and Natural Sciences, School of Medicine, University of Catania

2005-act Aggregate Professor of Hematology, School of Medicine, University of Catania

2000-2008 Professor of Hematology, PhD “Immunogenetic, Immunological and Technological Experimentations on application of the xenotransplantations and of the organ withdrawals for human transplantation” “XVI”, XXII, XXIII cicle, University of Catania.

2004-2011 Professor of Hematology PhD “Medical Embriology and Experimental Hematology and Pathology”, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII cicle

2018-act Professor of Hematology PhD “Precision medicin for health and health care” “I” cicle, University of Catania

2020-Elective Teaching Activity “Indicazioni al trapianto di cellule staminali ematopietiche”, Unversity of Catania

-**Invited Drafting Book** “Caratterizzazione isto ed immunologica dei linfomi non Hodgkin e

 loro correlazioni con la prognosi 1988, Chapter “ Indagini citobiologiche nelle emopatie

maligne: implicazioni cliniche”, pp. 43-52, ed. Dennis Quaglino e Girolamo Cretara 1988;

Elio Cacciola, Rosario Giustolisi, Patrizia Gugielmo, Damiano Murolo, Francesco Di Raimondo,

Giuseppe Milone, **Emma Cacciola**, Filippo Buscemi.

-**Invited Drafting Book** Biological role of pluripotent stem cell antigen CD34 in leukemic hematopoiesis

1994, Chapter “Molecular Biology of Haematopoiesis” – Vol. 3, pp 329-36, Eds. N. G. Abraha R.K. Shadduk

 – A. S. Levine – F. Takaku – Intercept Ltd PO Bpx 716, Andove Hants SP10 1YG, UK, 1994.

E. Cacciola, P. Guglielmo, **E. Cacciola jr.**, F. Stagno, S. Impera, G. Ferrigno and R. Giustolisi.

-**Invited Drafting Book**Hematopoietic growth factors, Oncogenes and Cytokines, in Clinical

Hematology 1994, Chapter “ Relationship between growth factors, oncogenes and cytokines in the

mechanism of aberrant hematopoiesis” pp. 1-21

Eds Cacciola E, Deisseroth AB, Giustolisi R, Karger, Basel.

Giuseppe A. Palumbo, **Emma Cacciola**, Patrizia Guglielmo, Rosario Giustolisi, Elio Cacciola.

-**Invited Drafting Book** “Manuale di Semeiotica e Metodologia Chirurgica” 2014, Chapter “Milza” pp. 239-248, Editors Francesco Basile, Rocco Bellantone, Biondi, Antonio Biondi, Giulio Di Candio, Gianlorenzo Dionigi, Ludovico Docimo, Celestino Pio Lombardi.

-Editors **Emma Cacciola,** Rossella Cacciola “Acta Haematologica” Vol. 97, No 1-2 per i tipi. Karger Basilea 1997 Chapter “Adhesion Molecules in Hematology”

1997-2001 Investigator for the ECLAP Study (European Collaboration on low dose Aspirin in

Polycythemia vera

2001-2003 Investigator for the PEG-Interferon alfa-2b in Essential Thrombocythemia: phase II

study for determination of the minimum effective, safe and tolerated doses

2005- Investigator for the GIMEMA protocol “Recurrent thrombosis among patients with

polycythemiavera and essential thrombocythemia. Retrospective analysis of the

incidence of the events, and of the efficacy and safety of secondary antithrombotic

prophylaxis”.

2006 Investigator for EXELS (Evaluation of Xagrid Efficacy and Long-Term Safety)

SPD422-401.

2008 Investigator for the GIMEMA protocol “A large-scale trial testing the intensity of

CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera (PV) – CYTO-PV”.

2008 Investigator for the GIMEMA protocol “Prospective evaluation of the predictive role

of JAK2V617F allele burden on clinical outcomes in patients with polycythemiavera”.

2008Investigator for the Shire Study SPD422-403 “A phase IIIb, randomised, open label study

to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus

hydroxyurea in high-risk essential thrombocythaemia patients”.

2010 Investigator for the**GIMEMA** “Retrospective evaluation of hydroxyurea treatment side

effects in Chronic myeloproliferative neoplasms”.

2010 Investigator for the**GIMEMA** “Retrospective evaluation of chronic myeloproliferative

neoplasmsin patients younger than 40 years”.

2013 Investigator for CVT-MNP (Cerebral Vein Thrombosis in Myeloproliferative Neoplasms)

Study.

2013 Investigator for “Prospective Observational Study in Women with thrombophilia and

Poliabortivity”

2014Investigator/Research Group for the FIR Research Project, University of Catania.

2015Investigator for the study “AVK/DOACSs-MPN Survey” Fondazione per la Ricerca

Ospedale Maggiore di Bergamo (FROM).

2016-act Investigator for the study “Recurrent ischemic stroke in Ph-negative Myeloproliferative

Neoplasms. The PRISM (Preventing Recurrent Ischemic Stroke in Myeloproliferative

Neoplasms). Fondazione per la Ricerca Ospedale Maggiore di Bergamo (FROM).

2016-actInvestigator for the study “Il profilo beneficio/rischio della Prolina-interferone-alfa-2b

peghilato (AOP2014), in aggiunta alla migliore strategia terapeutica disponibile basata sui

salassi, in pazienti con Policitemia Vera (PV) a basso rischio. Lo studio randomizzato

Low-PV.”Fondazione per la Ricerca Ospedale Maggiore di Bergamo (FROM).

2016-act **Outstanding Contribution Multidisciplinary Research Center named “Mini Invasive Surgical Techniques”** (2016-2021), University of Catania.

2016-act **Outstanding Contribution Multidisciplinary Research Center named “Diagnosis and Therapy of the Rare Diseases”**(2016-2021), University of Catania.

2017-act MAS Study “Measure And See” a START –FCSA study – Mesaurement of anticoagulant

levels in patients on direct oral anticoagulant (DOAC) and hemorrhagic and

thromboembolic complications during the follow-up. Multicenter, prospective and

observational study, START-FCSA.

2018-act Secondary Cancers inMyeloproliferative Neoplasms (MPN-K study).

Retrospective case control observational multicenter study “Fondazione per

la Ricerca Ospedale Maggiore di Bergamo (FROM) January 2018.

2018-act **Outstanding Contribution Multidisciplinary Research Center named Center Excellence for the Acceleration of HarmReduction (CoEHAR).**

2018-act Investigator/Research**“**The Jason study ”Secondary Prevention with sulodexide in eldeely patients after Venous Thromboembolism (VTE)”. Phase III, multicenter,national, randomized, placebo controlled, double bind study (no profit)” Research Group “Fondazione Arianna”- Bologna (Italy).

2018-act **High-Experience and High Level-Expertise Certificate of Teaching “Staff Development for senior teachers”, Area della Formazione Didattica, University of Catania, 18.06.2018**

**2020-National Scientific Qualification (ASN) as Associate Professor Academic Recruitment Field 06/D3 blood diseases, oncology and rheumatology – Academic Discipline MED/15 blood diseases, University of Catania**

**2020-act** **Pharmaceutical Training, Certicate of Graduation GOOD CLINICAL PRACTICE, Trainer: Stefano Lagravinese**

**2020-act Outstanding Contribution Multidisciplinary Research Center named “Molecular and Preclinic and Translational Imaging”**

**2020-act Outstanding Contribution Multidisciplinary Research Center named “Multidisciplinary Research Center for the diagnosis and therapy of the Fabry’s Disease and the Organ Transplant”**

**2020-act Positive evaluation result provided by the art. 6, paragraphs 7 and 8, of the Law 240/2010 for the purposes of partecipation in the procedure for the formation of local commissions, Academic Recruitment Field 06/D3 blood diseases, oncology and rheumatology – Academic Discipline MED/15 blood diseases, University of Catania**

**2020-Highly Transferable Teacher Quantitative Evaluation of Research (VQR) 2015-2019 Orcid 0000-0001-5735-9426**

**2020-act Research Unit Partecipanting - Research Project Pia.ce.ri (Piano di Incentivi per la Ricerca di Ateneo) 2020-2022 “Microbiome composition and peripheral blood immunome as early biomarkers of response in patients undergoing immnotherapy”, University of Catania**

**2021-act Outstanding Contribution Multidisciplinary Research Center named “Multidisciplinary Research Center in Papilloma Virus Pathology”**

**Invited Reviewer for international Scientific Journals**:

2005-act Reviewer for the journal “Drugs”

2016-act Reviewer for the journal “Thrombosis Research”

2017-act Reviewer for the journal “Leukemia Research”

**SocietyMembership:**

1989-act **Italian Society of Experimental Biology**

1991-act **New York Academy of Sciences**

1991-act **Italian Society of Hematology Membership n. 41**

1996-act **American Society of Hematology (ASH) Membership n. 0000127506**

2000-act **International Society on Thrombosis and Haemostasis (ISTH)Membership n. 4223**

2013-act **Federazione Centri per la Diagnosi e la Sorveglianza delle Terapie Antitrombotiche**

**(F.C.S.A.)**

F.C.S.A. is inserted bt the Ministry of Health Ministero in the listof the Scientific Society and of he Technical Scientific Association of the Health Care Professionsdelle Professioni Sanitarie DM August 2 2017

2020-act **European Hematology Association (EHA) Membership n. 079364**

**Scientific techniques and skills acquired:**

Biochemical assays: immunoenzymatic (ELISA), immunochemical, chromogenic, agarose gel electrophoresis and immunoblot in coagulation disorders (acquired and hereditary hemorrhagic and thrombotic diseases) and in myeloproliferative neoplasms. Platelet and coagulation functional tests: platelet aggregation and adhesion and thromboelastography. Genetic analysis: PCR and western blotting. Advanced statistical analysis.

Clinical and diagnostic management in the field of clinical hematology, onco-hematology, and arterial and venous thromboembolism. Therapeutic management of antineoplastic drugs (Janus Kinase, BKT, BCL2 inhibitors) and anticoagulant therapy (vitamin K Antagonists, Direct Oral Anticoagulants - DOACs).

**Publications:**

Prof. Emma Cacciola is author of over 300 peer reviewed papers in various international journals and meetings.